Massive Bio Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 100

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $16.5M

  • Investors
  • 20

Massive Bio General Information

Description

Developer of an artificial intelligence-driven platform intended to connect cancer patients to biopharmaceutical clinical trials. The company offers tech-enabled services and a big data platform that addresses the clinical trial enrollment value chain by providing patient identification, pre-screening, and concierge enrollment enablement while being focused on oncology and highly innovative data, technology, and services, enabling patients to get an effective treatment without disrupting lives and becoming a financial hindrance.

Contact Information

Website
www.massivebio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Other Healthcare Services
Information Services (B2C)
Application Software
Primary Office
  • 90 West Street
  • Suite 12M
  • New York, NY 10006
  • United States
+1 (844) 000-0000

Massive Bio Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Massive Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B1) 16-Dec-2022 $16.5M 000.00 0000 Completed Generating Revenue
4. Grant 17-Dec-2020 00000 00.000 Completed Generating Revenue
3. Later Stage VC (Series B) 30-Oct-2020 00.00 00.000 000.00 Completed Generating Revenue
2. Later Stage VC (Series A) 10-Apr-2019 $2.53M $2.78M 000.00 Completed Generating Revenue
1. Seed Round 01-Jul-2016 $250K $250K Completed Startup
To view Massive Bio’s complete valuation and funding history, request access »

Massive Bio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-1 000,000 00.000000 00.00 000.00 000.00 00 000.00 00.000
Series B-2 00,000 00.000000 00.00 000.00 000.00 00 000.00 0.000
Series A 89,144 $0.000100 $1.82 $30.33 $30.33 1x $30.33 6.62%
To view Massive Bio’s complete cap table history, request access »

Massive Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an artificial intelligence-driven platform intended to connect cancer patients to biopharmaceutical clinica
Other Healthcare Technology Systems
New York, NY
100 As of 2023
000.00
000 0000-00-00
00000000000 000.00

000000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
00000 0000000000 000
Singapore, Singapore
00 As of 0000
00.000
00.00 0000-00-00
0000000000 0 00.000

000000

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
00000 0000000000 000
London, United Kingdom
00 As of 0000
000.00
00.00 0000-00-00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Massive Bio Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oncoshot Venture Capital-Backed Singapore, Singapore 00 00.000 0000000000 0 00.000
00000000 Venture Capital-Backed London, United Kingdom 00 000.00 0000000000 0 000.00
You’re viewing 2 of 2 competitors. Get the full list »

Massive Bio Executive Team (11)

Name Title Board Seat Contact Info
Selin Kurnaz Ph.D Co-Founder & Chief Executive Officer
Cagatay Culcuoglu Co-Founder, Chief Operating Officer & Chief Technology Officer
Erkan Terzi Chief Marketing Officer and Vice President & Director of Global Marketing
Aymen Elfiky Co-Founder & CMIO
Oz Huner Chief Product Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Massive Bio Board Members (4)

Name Representing Role Since
Kenan Turnacioglu Ph.D Self Board Member 000 0000
Kevin Kojian Self Board Member 000 0000
You’re viewing 2 of 4 board members. Get the full list »

Massive Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Massive Bio Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
DEG PE/Buyout Minority 000 0000 000000 0
Gyan Kapur Angel (individual) Minority 000 0000 000000 0
International Finance Corporation Impact Investing Minority 000 0000 000000 0
Kenan Turnacioglu Angel (individual) Minority 000 0000 000000 0
Schusterman Family Investments Family Office Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Ready to get started?

Request a free trial